RESUMEN
Scalp psoriasis is a common manifestation of psoriasis that significantly impacts a patient's quality of life. About 80% of cases of psoriasis involve the scalp, making it the most frequently affected area of the body. The treatment of scalp psoriasis is particularly crucial because of its hard-to-treat nature and substantial adverse impacts on overall well-being. Along with the physical symptoms of discomfort and itching, psoriasis, especially when it affects the scalp, can cause severe psychological damage. Treating scalp psoriasis can be challenging due to its location and associated symptoms, such as scaling and pruritus, which is why various drugs have become widely used for refractory cases. Topical treatments like corticosteroids and vitamin D analogs manage scalp psoriasis by reducing inflammation and regulating skin cell growth. Tar-based shampoos, salicylic acid solutions, and moisturizers control scaling. Phototherapy with UVB light reduces inflammation. Severe cases may require systemic medications such as oral retinoids and immunosuppressants. While various therapies are accessible for scalp psoriasis, concerns arise due to their limited advantages and the absence of controlled studies assessing their effectiveness. Considering these challenges, there is a clear demand for innovative approaches to address this condition effectively. Recent advancements in topical therapies, phototherapy, systemic agents, and complementary therapies have shown promising results in managing scalp psoriasis. Also, the advent of biologics, specifically anti-IL-17 and anti-IL-23 drugs for scalp psoriasis, has seen significant improvements. The review highlights the lack of well-tolerated and effective treatments for scalp psoriasis and underscores the importance of further research in this area. The objective of this review is to clarify the different treatment options currently available or being investigated in clinical trials for managing scalp psoriasis.
Asunto(s)
Psoriasis , Humanos , Psoriasis/terapia , Psoriasis/tratamiento farmacológico , Fármacos Dermatológicos/uso terapéutico , Calidad de Vida , Fototerapia/métodos , Cuero Cabelludo/patología , Dermatosis del Cuero Cabelludo/tratamiento farmacológico , Dermatosis del Cuero Cabelludo/terapiaRESUMEN
Pressure-induced alopecias (PAs) are an infrequent group of scarring and nonscarring alopecias that occur after ischemic obstruction of capillaries that leads to circumscribed areas of hair loss. Initially described after prolonged surgeries or immobilization, type 1 PA occurs after sustained external pressure to the skin, mainly the scalp prominences. Alopecia induced by cosmetic procedures, referred in this review as type 2 PA, is reported with increased frequency in literature and predominantly emerges from pressure exerted by the volume of injectables. It is important to differentiate type 2 PA from vascular occlusion-induced alopecia because they represent distinct entities. Clinically, PA may present with erythema, swelling, and tenderness; however, alopecia might be the sole manifestation. Crusts and ulceration are associated with a worse outcome and a higher risk of scarring alopecia. Prompt diagnosis is paramount to prevent complications. Trichoscopy, although considered nonspecific, may provide relevant clues for an accurate diagnosis. Hair regrows in most cases, but prognosis depends on ischemia severity and timely treatment with reperfusion therapies or mobilization. Treatment of hair loss is usually not necessary because the disease in most cases is self-limited and reversible. The role of topical minoxidil and corticosteroids remains unknown.
Asunto(s)
Alopecia , Cicatriz , Humanos , Cicatriz/terapia , Cicatriz/complicaciones , Alopecia/diagnóstico , Alopecia/etiología , Alopecia/terapia , Cabello/patología , Cuero Cabelludo/patología , PielRESUMEN
Many patients with moderate-to-severe psoriasis may not achieve complete skin clearance with recalcitrant lesions despite being on biologics. We aimed to evaluate the real-world effectiveness and safety of combining topical calcipotriene/betamethasone dipropionate (Cal/BD) foam with biologic therapy for the treatment of recalcitrant psoriatic lesions over the scalp or lower legs. We retrospectively reviewed the medical charts of psoriasis patients receiving adjunctive topical Cal/BD foam with biologics for at least 16 weeks on recalcitrant psoriatic lesions of the scalp or lower legs between 2020 and 2021 at a tertiary referral medical center in southern Taiwan. Among the 18 recruited patients, the severity outcomes of body surface area (BSA), Physician's Global Assessment (PGA), and BSA × PGA of the recalcitrant areas decreased by approximately 31%, 48%, and 50%, respectively, after 4 weeks of once-daily adjunctive Cal/BD foam use. Thereafter, the effect remained nearly constant after dose reduction to twice weekly until week 16. The Dermatology Life Quality Index and the nine-item Treatment Satisfaction Questionnaire for Medication questionnaire revealed improved life quality and a high level of satisfaction, with only a few mild adverse effects reported. In conclusion, adjunctive topical Cal/BD foam might be an effective and safe option for patients with recalcitrant lesions on the scalp and lower legs despite biologics use.
Asunto(s)
Productos Biológicos , Fármacos Dermatológicos , Psoriasis , Humanos , Cuero Cabelludo/patología , Pierna , Estudios Retrospectivos , Fármacos Dermatológicos/uso terapéutico , Combinación de Medicamentos , Resultado del Tratamiento , Psoriasis/patología , Betametasona , Terapia Biológica , Productos Biológicos/uso terapéuticoRESUMEN
BACKGROUND: Erosive pustular dermatosis of the scalp (EPDS) is a rare inflammatory disorder of elderly individuals, characterized by relapsing pustular and eroded lesions of the scalp, which may lead to scarring alopecia. Treatment is challenging and classically based on topical and/or oral corticosteroids. CASE REPORT: From 2008 to 2022, we treated fifteen cases of EPDS. We used mainly topical and systemic steroids with good results. Nevertheless, several non-steroidal topical drugs have been described in literature for the treatment of EPDS. We have carried out a brief review of these treatments. CONCLUSIONS: Topical calcineurin inhibitors represent a valuable alternative to steroids to avoid skin atrophy. Emerging evidence about other topical treatments, such as calcipotriol, dapsone, zinc oxide, together with photodynamic therapy, are evaluated in our review.
Asunto(s)
Dermatosis del Cuero Cabelludo , Cuero Cabelludo , Humanos , Anciano , Cuero Cabelludo/patología , Dermatosis del Cuero Cabelludo/tratamiento farmacológico , Dermatosis del Cuero Cabelludo/patología , Administración Tópica , Dapsona/uso terapéutico , Alopecia/tratamiento farmacológicoRESUMEN
BACKGROUND: Evidence suggests that the pathogenesis of Parkinson's disease (PD) is initiated in the gut rather than in the brain. Thus, targeting the gut in early stages may have the potential to halt disease progression and alleviate symptoms. Various acupuncture techniques have been used to treat patients with PD and have shown promising results. However, previous acupuncture techniques focused on the brain and motor symptoms. We aimed to determine if targeting PD patients' gut-brain axis through electroacupuncture could be an effective, safe, and low-cost therapeutic option for management of non-motor and motor symptoms. METHODS: Thirty patients with mild to moderate PD were randomised into an intervention (n = 15) and a control group (n = 15). The intervention group received electroacupuncture twice a week for 30 min based on conventional drug treatment for 8 weeks. Conventional drug treatment was continued in the control group. The primary outcomes were changes in the score of clinical scales including the Non-motor Symptom Rating Scale (NMSS), PD Sleep Scale (PDSS), Bristol Stool Function Scale (BSFS), and Patient Associated Constipation and Quality of Life Scale (PAC-QOL). The secondary outcomes were the Unified PD Rating Scale (UPDRS) and Modified Hoehn-Yahr Staging Scale scores. Stool samples from the intervention group were collected before and after the procedure and were sent for gene sequencing. Adverse effects and personal impressions of the patients were noted during the course of the trial. RESULT: An 8-week course of scalp-abdominal electroacupuncture treatment was effective in improving the NMSS, PDSS, and UPDRS scores in patients with PD. Further, there was statistical significance in the two subdomains of NMSS, namely sleep/fatigue and miscellaneous, further implying the efficacy of acupuncture on sleep disturbance. However, although the current acupuncture treatment was gut targeted, it had no effect on BSFS or PAC-QOL. Apart from improved UPDRS motor scores and activities of daily living scores, acupuncture had no significant impact on scores of mentation, behaviour, mood, and therapy complications. Acupuncture did not alter the Hoehn and Yahr stage. Significant alterations in gut bacterial composition were detected in nine taxa at the genus level. The relative abundances of the genera Bacteroides and Parasutterella were significantly increased after the intervention, whereas the abundances of the genera Dialister, Hungatella, Barnesiella, Megasphaera, Allisonella, Intestinimon, and Moryella were significantly lower. CONCLUSION: An 8-week scalp-abdominal electroacupuncture treatment may be a complementary and alternative vehicle for PD patients. We detected nine taxa at the genus level which were significantly altered after treatment, emphasising the role of the gut-brain axis in the process.
Asunto(s)
Electroacupuntura , Enfermedad de Parkinson , Actividades Cotidianas , Eje Cerebro-Intestino , Electroacupuntura/métodos , Humanos , Enfermedad de Parkinson/patología , Calidad de Vida , Cuero Cabelludo/patologíaRESUMEN
BACKGROUND: Chemotherapy-induced alopecia (CIA) is a common and quite distressing adverse effects of chemotherapy. There are few detailed observational studies of CIA or of the impact of age on CIA. We performed a prospective observational study to investigate the prevalence and degree of CIA, including CIA of eyebrows, eyelashes, and body, and we examined patient's recovery from CIA, focusing on age-depending effects. METHODS: We analyzed 68 female Japanese patients with breast cancer (median age 53 years, range 29-76 years) who received perioperative adjuvant chemotherapy with fluorouracil/epirubicin/cyclophosphamide (FEC) and taxane. A questionnaire was administered at the point of chemotherapy completion and 6 and 12 months after chemotherapy completion. RESULTS: CIA occurred in all patients, with severe hair loss irrespective of age. CIA occurred mainly in the scalp but also in the eyebrows, eyelashes, and body for most of the patients. There were significant associations between the patient's age and the onset of hair regrowth in the eyebrows, eyelashes, and body. The onset of eyebrows, eyelash, and body hair growth were significantly shorter in the premenopausal patients. Any hair changes (e.g., thinned diameter, softer texture, curlier structure) were reported by 85.3% of the patients. CONCLUSIONS: Severe CIA occurred in all 68 patients who received FEC and taxane chemotherapy. The present findings provide the first data demonstrating that age was not associated with the degree or incidence of hair loss, but age affected the recovery from CIA. These results contribute more accurate information provision and insights regarding the proper treatment of CIA.
Asunto(s)
Alopecia/inducido químicamente , Antineoplásicos/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias de la Mama/tratamiento farmacológico , Hidrocarburos Aromáticos con Puentes/efectos adversos , Taxoides/efectos adversos , Adulto , Factores de Edad , Anciano , Alopecia/epidemiología , Ciclofosfamida/efectos adversos , Epirrubicina/efectos adversos , Cejas/patología , Pestañas/patología , Femenino , Fluorouracilo/efectos adversos , Humanos , Japón/epidemiología , Persona de Mediana Edad , Premenopausia , Prevalencia , Estudios Prospectivos , Cuero Cabelludo/patología , Autoinforme , Resultado del TratamientoAsunto(s)
Neoplasias de los Conductos Biliares/diagnóstico , Colangiocarcinoma/secundario , Neoplasias de Cabeza y Cuello/secundario , Cuero Cabelludo/patología , Neoplasias Cutáneas/secundario , Neoplasias de los Conductos Biliares/patología , Neoplasias de los Conductos Biliares/terapia , Conductos Biliares Intrahepáticos/diagnóstico por imagen , Conductos Biliares Intrahepáticos/patología , Biomarcadores de Tumor/análisis , Biopsia , Colangiocarcinoma/diagnóstico , Colangiocarcinoma/terapia , Terapias Complementarias , Neoplasias de Cabeza y Cuello/diagnóstico , Neoplasias de Cabeza y Cuello/terapia , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/terapia , Tomografía Computarizada por Rayos XAsunto(s)
Alopecia/radioterapia , Enfermedades Genéticas Ligadas al Cromosoma X/radioterapia , Ictiosis/radioterapia , Láseres de Semiconductores/uso terapéutico , Terapia por Luz de Baja Intensidad/instrumentación , Enfermedades Cutáneas Genéticas/radioterapia , Alopecia/etiología , Biopsia , Enfermedades Genéticas Ligadas al Cromosoma X/complicaciones , Humanos , Ictiosis/complicaciones , Masculino , Cuero Cabelludo/patología , Cuero Cabelludo/efectos de la radiación , Piel/patología , Piel/efectos de la radiación , Enfermedades Cutáneas Genéticas/complicaciones , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUNDS: Androgenic alopecia is a common and unpleasant problem that directly influences the self-confidence and individual life quality. There are various treatment choices that currently are used by people suffering from androgenic alopecia. Drug therapies (e. g. minoxidil, finasteride, dutasteride, prostaglandin analogues, ketoconazole, Cyproterone acetate and spironolactone), Laser-light treatment, surgical treatment, cell mediated treatment and alternative treatments (vitamin, mineral and herbal components) are common therapeutic methods suggested for management of androgenic alopecia. Herbal medicines are now commonly used all over the world and this has increased global demand. Quality, safety and efficacy of these drugs have become a serious concern. OBJECTIVES: The aim of this review is evaluating the herbal or fungal medicines were used in androgenic alopecia and introducing the phytochemicals, biological effects, responsible constituents and the mechanism of this action. RESULTS: The 23 medicinal fungi or plants with their possible mechanisms and active phytoconstituents, which were used in androgenic alopecia are described. METHODS/DESIGN: In this review, most of the natural sources that used in the treatment of androgenic alopecia were collected from electronic databases including Web of Science, PubMed, Scopus and Google Scholar were searched for these plants. Data were gathered from 1970 to 2016. CONCLUSION: The summarized findings in this article could be inspiration to product new formulations for treatment of androgenic alopecia with more effective properties and fewer side effect.
Asunto(s)
Alopecia/tratamiento farmacológico , Medicina de Hierbas , Fitoterapia , Plantas Medicinales , Alopecia/patología , Finasterida , Humanos , Minoxidil , Cuero Cabelludo/patologíaRESUMEN
OBJECTIVE: To determine the current state of knowledge and provide evidence-based recommendations that could be valid for all specialists taking care of female pattern hair loss (FPHL), a common form of hair loss in women that is characterized by the reduction of hair density in the central area of the scalp, whereas the frontal hairline is generally well conserved. PARTICIPANTS: An expert task force appointed by the Androgen Excess and PCOS Society, which included specialists from dermatology, endocrinology, and reproductive endocrinology. DESIGN: Levels of evidence were assessed and graded from A to D. Peer-reviewed studies evaluating FPHL published through December 2017 were reviewed. Criteria for inclusion/exclusion of the published papers were agreed on by at least two reviewers in each area and arbitrated by a third when necessary. CONCLUSIONS: (i) The term "female pattern hair loss" should be used, avoiding the previous terms of alopecia or androgenetic alopecia. (ii) The two typical patterns of hair loss in FPHL are centrifugal expansion in the mid scalp, and a frontal accentuation or Christmas tree pattern. (iii) Isolated FPHL should not be considered a sign of hyperandrogenism when androgen levels are normal. (iv) The assessment of patients with FPHL is primarily clinical. (v) In all patients with FPHL, assessment of a possible androgen excess is mandatory. Measurement of vitamin D, iron, zinc, thyroid hormones, and prolactin are optional but recommended. (vi) Treatment of FPHL should start with minoxidil (5%), adding 5α-reductase inhibitors or antiandrogens when there is severe hair loss or hyperandrogenism.
Asunto(s)
Alopecia/diagnóstico , Hiperandrogenismo/diagnóstico , Inhibidores de 5-alfa-Reductasa/uso terapéutico , Alopecia/epidemiología , Alopecia/patología , Alopecia/terapia , Antagonistas de Andrógenos/uso terapéutico , Femenino , Humanos , Hiperandrogenismo/tratamiento farmacológico , Hiperandrogenismo/epidemiología , Hiperandrogenismo/metabolismo , Terapia por Luz de Baja Intensidad , Antagonistas de Receptores de Mineralocorticoides/uso terapéutico , Minoxidil/uso terapéutico , Plasma Rico en Plaquetas , Síndrome del Ovario Poliquístico/epidemiología , Síndrome del Ovario Poliquístico/metabolismo , Cuero Cabelludo/patología , Espironolactona/uso terapéutico , Vasodilatadores/uso terapéuticoRESUMEN
To compare the efficacy and safety of UVA1 and narrowband UVB (NB-UVB) therapy in the treatment of scalp psoriasis. Patients with scalp psoriasis were randomly assigned to either UVA1 or NB-UVB therapy. Both treatments were performed three times weekly for 6 weeks. Clinical efficacy was evaluated by using Psoriasis Scalp Severity Index (PSSI), and patient-reported quality of life (QoL) was assessed by Dermatology Life Quality Index (DLQI). Totally 68 patients completed the study. Both UVA1 and NB-UVB phototherapy achieved a statistically significant reduction of PSSI and DLQI scores at the end of the treatment period. Compared with the NB-UVB group, the significantly greater improvements occurred in UVA1 treatment group at week 3, although differences declined thereafter through week 10. Both UVA1 and NB-UVB therapy were well-tolerated in this study, and the occurrence of adverse events (AEs) was uncommon. Both UVA1 and NB-UVB phototherapy could offer relief of scalp symptoms in patients with scalp involvement. Furthermore, UVA1 treatment could improve the clinical manifestations and QoL more quickly than NB-UVB therapy.
Asunto(s)
Psoriasis/radioterapia , Cuero Cabelludo/patología , Cuero Cabelludo/efectos de la radiación , Terapia Ultravioleta , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Calidad de Vida , Resultado del Tratamiento , Terapia Ultravioleta/efectos adversos , Adulto JovenAsunto(s)
Alopecia/tratamiento farmacológico , Dermatología/ética , Marihuana Medicinal/uso terapéutico , Cuero Cabelludo/patología , Alopecia/patología , Prescripciones de Medicamentos , Femenino , Fibrosis , Humanos , Marihuana Medicinal/efectos adversos , Persona de Mediana Edad , Prioridad del PacienteRESUMEN
BACKGROUND: Phototherapy can be an option in unresponsive alopecia areata (AA); however, variable results have been reported with its use. We could not find literature of treatment with UVA-1 in AA. A study was designed to evaluate progressive dosimetry to determine the initial dose and its increments. METHODS: Patients with unresponsive AA were recruited. Twenty-five sessions of 30 J/cm2 were administered. If hair regrowth was <75%, the dose was escalated to 60 J/cm2 . If hair improvement remained <75%, an additional 25 sessions at 120 J/cm2 were indicated. If total hair regrowth occurred before 75 sessions, a final visit was performed for biopsies and severity of alopecia tool (SALT) evaluation. Clinical and histopathological assessments were performed blindly. Adverse effects were recorded. RESULTS: Nine men and 13 women were included; 16 were initially S1 , one S3 , and five S4 . Median age was 32 years and median evolution 10 months. Nine patients achieved an S0 , eight S1 , and five S4 (P = 0.005). The most notable improvement was with 60 J/cm2 (P = 0.02). Biopsies exhibited an absence of inflammation in five patients and mild persistence in 17. An increase of 43.75% in anagen hairs (P ≤ 0.001) was achieved, telogen hairs decreased 16.3% (P = 0.06), and catagen hairs were reduced 22.7% (P = 0.005). Pearson's correlation was -0.82 and P ≤ 0.001, when correlating anagen hairs with final SALT. Improvement has continued for 6 months post treatment. Mild xerosis was observed in all patients, and six (28.6%) developed transient mild hyperpigmentation. CONCLUSIONS: This study provides a basis for UVA-1 dosimetry evaluating its therapeutic value in AA.
Asunto(s)
Alopecia Areata/radioterapia , Folículo Piloso/patología , Terapia Ultravioleta/métodos , Adulto , Alopecia Areata/tratamiento farmacológico , Alopecia Areata/patología , Femenino , Cabello/crecimiento & desarrollo , Folículo Piloso/efectos de la radiación , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Dosificación Radioterapéutica , Retratamiento , Cuero Cabelludo/patología , Índice de Severidad de la Enfermedad , Terapia Ultravioleta/efectos adversosRESUMEN
BACKGROUND: Scalp psoriasis is commonly the initial presentation of psoriasis, and almost 80 % of patients with psoriasis will eventually experience it. OBJECTIVE: Although several systematic reviews and guidelines exist, an up-to-date evidence-based review including more recent progress on the use of biologics and new oral small molecules was timely. METHODS: Of the 475 studies initially retrieved from PubMed and the 845 from Embase (up to May 2016), this review includes 27 clinical trials, four papers reporting pooled analyses of other clinical trials, ten open-label trials, one case series, and two case reports after excluding non-English literature. RESULTS: To our knowledge, few randomized controlled trials (RCTs) are conducted specifically in scalp psoriasis. Topical corticosteroids provide good effects and are usually recommended as first-line treatment. Calcipotriol-betamethasone dipropionate is well tolerated and more effective than either of its individual components. Localized phototherapy is better than generalized phototherapy on hair-bearing areas. Methotrexate, cyclosporine, fumaric acid esters, and acitretin are well-recognized agents in the treatment of psoriasis, but we found no published RCTs evaluating these agents specifically in scalp psoriasis. Biologics and new small-molecule agents show excellent effects on scalp psoriasis, but the high cost of these treatments mean they may be limited to use in extensive scalp psoriasis. CONCLUSIONS: More controlled studies are needed for an evidence-based approach to scalp psoriasis.
Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Psoriasis/terapia , Cuero Cabelludo/patología , Productos Biológicos/administración & dosificación , Productos Biológicos/uso terapéutico , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/efectos adversos , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Glucocorticoides/uso terapéutico , Humanos , Fototerapia/métodos , Psoriasis/patología , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
BACKGROUND: Precision medicine approaches are ideally suited for rare tumors where comprehensive characterization may have diagnostic, prognostic, and therapeutic value. We describe the clinical case and molecular characterization of an adolescent with metastatic poorly differentiated carcinoma (PDC). Given the rarity and poor prognosis associated with PDC in children, we utilized genomic analysis and preclinical models to validate oncogenic drivers and identify molecular vulnerabilities. METHODS: We utilized whole exome sequencing (WES) and transcriptome analysis to identify germline and somatic alterations in the patient's tumor. In silico and in vitro studies were used to determine the functional consequences of genomic alterations. Primary tumor was used to generate a patient-derived xenograft (PDX) model, which was used for in vivo assessment of predicted therapeutic options. RESULTS: WES revealed a novel germline frameshift variant (p.E1554fs) in APC, establishing a diagnosis of Gardner syndrome, along with a somatic nonsense (p.R790*) APC mutation in the tumor. Somatic mutations in TP53, MAX, BRAF, ROS1, and RPTOR were also identified and transcriptome and immunohistochemical analyses suggested hyperactivation of the Wnt/ß-catenin and AKT/mTOR pathways. In silico and biochemical assays demonstrated that the MAX p.R60Q and BRAF p.K483E mutations were activating mutations, whereas the ROS1 and RPTOR mutations were of lower utility for therapeutic targeting. Utilizing a patient-specific PDX model, we demonstrated in vivo activity of mTOR inhibition with temsirolimus and partial response to inhibition of MEK. CONCLUSIONS: This clinical case illustrates the depth of investigation necessary to fully characterize the functional significance of the breadth of alterations identified through genomic analysis.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma/tratamiento farmacológico , Carcinoma/genética , Genómica/métodos , Enfermedades Raras/tratamiento farmacológico , Enfermedades Raras/genética , Adolescente , Animales , Carboplatino/efectos adversos , Carcinoma/diagnóstico por imagen , Análisis Mutacional de ADN , Etopósido/efectos adversos , Resultado Fatal , Humanos , Masculino , Ratones Endogámicos NOD , Ratones Noqueados , Ratones SCID , Paclitaxel/efectos adversos , Enfermedades Raras/diagnóstico por imagen , Cuero Cabelludo/efectos de los fármacos , Cuero Cabelludo/metabolismo , Cuero Cabelludo/patología , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Dandruff is a common cosmetic condition associated with flaky scalp skin and pruritus. It is generally treated with regular use of antifungal-based shampoos. Research into factors underlying the characteristic skin lesions has revealed perturbations in epidermal differentiation and a dramatic deterioration in the associated process of stratum corneum (SC) maturation. These observations suggest that directly addressing the quality of the SC could have a scalp benefit. In this study, the authors investigated the efficacy of a moisturising leave-on lotion (LOL) containing a high concentration of glycerol (10%) and other known skin benefit agents (saturated fatty acid and sunflower seed oil) to reduce dandruff over an 8-week treatment period with 3 applications per week. Results of expert visual grading and biophysical measurements of SC parameters (transepidermal water loss and hydration) revealed a significant reduction in the dandruffcondition over this period, with significant improvement in both SC water barrier function and hydration. These scalp skin benefits were maintained for up to a week following cessation of the treatment. This study indicates that use of a glycerol-rich substantive LOL, designed to directly improve the quality of the SC barrier can have a significant impact on the dandruff condition.